Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort

Simple item page
dc.contributor.authorCalderón Parra, Jorge
dc.contributor.authorGuisado Vasco, Pablo
dc.contributor.authorMontejano Sánchez, Rocío
dc.contributor.authorEstrada Pérez, Vicente
dc.contributor.authorCuevas Tascón, Guillermo
dc.contributor.authorAguareles Gorines, José
dc.contributor.authorArribas, José
dc.contributor.authorErro Iribarren, Marta
dc.contributor.authorCalvo Salvador, Marina
dc.contributor.authorFernández Cruz, Ana
dc.contributor.authorRamos Martínez, Antonio
dc.contributor.authorMuñez Rubio, Elena
dc.date.accessioned2023-06-22T11:19:53Z
dc.date.available2023-06-22T11:19:53Z
dc.date.issued2023
dc.descriptionThis work was supported by the Research Institute Puerta de Hierro-Segovia de Aranda (IDIPHSA), funding number 0040200108 (2.400€).
dc.description.abstractObjective: We aim to describe the safety and efficacy of sotrovimab in severe cases of COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter cohort including immunocompromised hospitalized patients with severe COVID-19 treated with sotrovimab between October 2021 and December 2021. Results: We included 32 patients. The main immunocompromising conditions were solid organ transplantation (46.9%) and hematological malignancy (37.5%). Seven patients (21.9%) had respiratory progression: 12.5% died and 9.4% required mechanical ventilation. Patients treated within the first 14 days of their symptoms had a lower progression rate: 12.0% vs. 57.1%, p = 0.029. No adverse event was attributed to sotrovimab. Conclusions: Sotrovimab was safe and may be effective in its use for immunocompromised patients with severe COVID-19. More studies are needed to confirm these preliminary data.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.sponsorshipResearch Institute Puerta de Hierro-Segovia de Aranda (IDIPHSA)
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/78393
dc.identifier.doi10.3390/jcm12030864
dc.identifier.issn2077-0383
dc.identifier.officialurlhttps://doi.org/10.3390/jcm12030864
dc.identifier.relatedurlhttps://www.mdpi.com/journal/jcm
dc.identifier.urihttps://hdl.handle.net/20.500.14352/72323
dc.issue.number3
dc.journal.titleJournal of Clinical Medicine
dc.language.isoeng
dc.page.initial864
dc.publisherMDPI
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.cdu616.98:578.834
dc.subject.cdu578.834:616.98
dc.subject.cdu612.017
dc.subject.keywordCOVID-19
dc.subject.keywordMonoclonal antibodies
dc.subject.keywordSotrovimab
dc.subject.keywordSevere COVID-19
dc.subject.keywordImmunocompromised hosts
dc.subject.ucmEnfermedades infecciosas
dc.subject.unesco3205.05 Enfermedades Infecciosas
dc.titleUse of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort
dc.typejournal article
dc.volume.number12
dspace.entity.typePublication
relation.isAuthorOfPublicatione883361d-f29e-4471-9099-3007d443ca6a
relation.isAuthorOfPublicationdc005ffc-7eba-4a0e-8450-5a2450dacc15
relation.isAuthorOfPublication.latestForDiscoverye883361d-f29e-4471-9099-3007d443ca6a
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jcm-12-00864.pdf
Size:
1.21 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos